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ABSTRACT
Hepatitis C (HCV) is a common form of liver disease encountered in pregnancy. The
purpose of this study is to evaluate if hepatitis C is associated with elevated maternal
serum bile acids and abnormal fetal cardiac function measured by the left ventricular
Tei index in the absence of intrahepatic cholestasis of pregnancy. This is a prospective
cohort study on pregnant women with hepatitis C seen through Marshall University’s
high-risk obstetrics clinic from 2013 to 2014. Women with hepatitis C had a laboratory
evaluation and an ultrasound on the fetus to calculate the left ventricular Tei index.
Demographic information and delivery outcomes were recorded. Seventy-seven
participants with hepatitis C were recruited and consented for this study. Sixty-one
participants had complete laboratory and delivery information available for analysis.
Twenty-one participants had a viral load that was not detectable and forty participants
had a detectable viral load. The mean viral load overall was 1943771 IU/mL (SD
4257143). There was no difference in Tei index between detectable and non-detectable
viral load, 0.41 and 0.38 respectively (p = 0.41). There was no statistical difference in bile
acid level between detectable and undetectable viral load, 12 and 8 µmol/L respectively
(p = 0.05). Hepatic liver disease manifested by elevated hepatitis C viral load or elevated
bile acids did not affect the left ventricular Tei index.
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INTRODUCTION
Hepatitis C (HCV) is the most common bloodborne pathogen in the United States.1,2 It is caused
by a single stranded RNA virus in the Flaviviridae
family.3 A recent study in 2015 estimated that 3.5
million people are currently infected with HCV in
the United States.4 Hepatitis C can be transmitted
through various modes including bodily fluids,
blood, intravenous drug use, needle stick injuries,
vertical transmission at birth, sexual activity, or
sharing of personal items with infected blood.5,6 The
exact incidence of HCV in pregnancy is unknown
as current guidelines recommend risk-factor based
screening; it is thought, however, that it affects
1-1.6% of pregnancies and rising.7-9 There have been
suggestions to consider initiation of population-level
screening as high rates of poor obstetrical outcomes
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have been found in prospective cohorts that are HCV
positive.10 In the Appalachia region it has become
an increasingly concerning public health issue.2
According to the CDC, in West Virginia between 20092013 reported rates of acute hepatitis C increased by
82%.11
Intrahepatic cholestasis of pregnancy affects
approximately 1% of pregnancies and is characterized
by pruritus and elevated aminotransferases.12 The
pruritus is notable as it is often described specifically
on the palms of patient’s hands and the soles of
their feet. Patients diagnosed with intrahepatic
cholestasis of pregnancy are at risk for adverse
pregnancy outcomes including meconium stained
amniotic fluid, intrauterine fetal demise, postpartum hemorrhage and premature delivery.13,14
Pregnancies complicated by HCV are at increased
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risk for being affected by intrahepatic cholestasis of
pregnancy (ICP). In a study by Belay et al involving
91 patients with a diagnosis of HCV, 41 of those
(45%) were also diagnosed with ICP.15 Their study
also showed significantly higher median viral load
when comparing HCV-infected patients with ICP
to HCV-infected patients without ICP (495,000 vs.
8000 copies/mL, P<0.001). Clinically, in patients
diagnosed with ICP infection with hepatitis C, some
hypothesize that HCV may actually worsen the
pruritus in late pregnancy due to increasing levels of
estrogen and progesterone.12
The Tei index is an ultrasound technique that
measures global cardiac function, relying less on
anatomy and precise imaging and being independent
of heart rate and ventricular geometry.16 It expresses
global function using a ratio incorporating both

systolic and diastolic time intervals (Figure I a
and b).17 Through measurement of the Tei index,
studies have shown left ventricular dysfunction
and myocardial injury in neonates with maternal
diagnosis of ICP.18,19 Cummings et al evaluated the
left ventricular Tei index in pregnancies affected by
ICP, showing similar results that fetuses affected by
ICP had Tei indices that were significantly elevated
compared to Tei indices of control fetuses20.
However, more than half of the pregnancies were
also complicated by HCV.20 It is unknown if the
changes seen in the Tei index of these fetuses
were due to HCV or ICP, both of which cause liver
dysfunction.
There is a growing number of pregnant women
being infected with HCV and limited data on the
myocardial effects on the fetus. The purpose of this

FIGURE I (B)

MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 4 Issue 2

study was to evaluate if hepatitis C is associated
with elevated maternal serum bile acids and
abnormal fetal cardiac function measured by the left
ventricular Tei index in the absence of the diagnosis
of ICP.
MATERIALS AND METHODS
This is a prospective cohort study on pregnant
women with HCV seen through the Marshall
University’s obstetric high-risk clinic in Huntington,
WV from 2013 to 2014. Ethics approval was obtained
through the institutional review board. Pregnant
women were screened for HCV based on history
of substance abuse, current substance abuse/
dependence or a positive urine drug screen. A
positive HCV screen was followed up with an
additional maternal laboratory evaluation (hepatitis
C quantitative PCR viral load, liver chemistry
panel and fasting serum bile acids). An ultrasound
was performed on the fetus to calculate the left
ventricular Tei index. The ultrasound studies
were performed with a C15 and AB2-7 transducer
with 1 of 2 scanners (Voluson 8 and Voluson
730 Expert). One of six registered diagnostic
medical sonographers preformed the Doppler
echocardiography. The medical sonographers
routinely perform fetal Tei indices, and the
measurements were corroborated by a maternal
fetal medicine specialist. Participants were excluded
from the study if they had a diagnosis of ICP before
enrollment.
All data was summarized by HCV viral load group
as the mean and standard deviation for continuous
measures and frequency and percentage for
categorical variables. Depending on the continuous
outcome distribution, statistical analysis utilized
either two-sample t-test or Wilcoxon rank-sum
test. For binary response, chi-square test statistic
or Fisher’s exact test was used as appropriate.
All analyses were based on a 2-sided test with
significance level of 0.05. Pregnancy complications
and delivery outcomes were also collected.
RESULTS
Seventy-seven participants with HCV were recruited
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and consented for this study. Sixty-one participants
had complete laboratory and delivery information
available for analysis (Table 1). Twenty-one
participants had a viral load that was not detectable
and forty participants had a detectable viral load.
The mean viral load overall was 1943771 IU/mL
(SD 4257143). There was no difference in Tei index
between detectable and non-detectable viral load,
0.41 and 0.38 respectively (p = 0.41). There was
no statistical difference in bile acid level between
detectable and undetectable viral load, 12 and 8
µmol/L respectively (p = 0.05).
Overall the mean alanine aminotransferase
(ALT) was 52 U/L (SD 77). Among women with a
detectable viral load, the mean ALT was 63 U/L
(SD 77) compared to the non-detectable group
31 U/L (SD 74); p <0.0001. The mean aspartate
aminotransferase (AST) overall was 46 U/L (SD 59);
AST in the group with a detectable viral load was 57
U/L (SD 68) compared to 26 U/L (SD 27) in the nondetectable group; p = 0.0011. The mean Tei index
overall was 0.40 (SD 0.11); Tei index in the detectable
viral load was 0.41 (0.11) compared to 0.38 (SD 0.08)
in the non-detectable group; p=0.41.
The ALT, AST, Tei index and bile acids were
dichotomized with HCV viral load (Table 2). The
normal ALT range for the laboratory used was 12-78
U/L. The ALT was abnormal in 9 (23%) subjects in the
detectable viral load group and 1 (5%) in the nondetectable group; p = 0.14. The normal AST range
for the laboratory used was 15-37 U/L. The AST was
abnormal in 14 (35%) subjects in the detectable viral
load and 1 (5%) subject in the non-detectable group;
p = 0.01. The Tei index was considered normal if less
than or equal to 0.36.21 The Tei index was abnormal
in 23 (58%) subjects in the detectable viral load
group and in 12 (57%) subjects in the non-detectable
group; p =1.0. The bile acids were abnormal in 15
(38%) subjects in the detectable viral load and in 5
(24%) subjects in the non-detectable group; p = 0.39.
DISCUSSION
A growing number of pregnant women are infected
with HCV and its effect on the fetal myocardium
has not yet been fully elucidated. Hepatitis C
infection and ICP are both known factors causing

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 4 Issue 2

TABLE 1: Maternal and infant measures

TABLE 2: Measure of association between ALT, AST, Bile acid, Tei index with HCV VL
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liver dysfunction and adverse fetal effects but due
to pathologic overlap the management of patients
with these diseases can be difficult. Some have
simply referred to these disorders as a whole, using
the term obstetric cholestasis in the context of
several disorders including HCV, acute fatty liver of
pregnancy, or adverse drug reactions.22 Non-invasive
antenatal testing and precise diagnosis of the
underlying liver disorder should continue to be the
goal as an accurate diagnosis can potentially lead to
more targeted therapy for both mother and fetus.
An advantage of our study was the final
measurement and calculation of the Tei index by a
maternal-fetal medicine specialist. By having a single
interpreter we were able to consistently reciprocate
accurate measurements because of no variability
between interpreters. Furthermore, all lab tests were
drawn and analyzed at one laboratory, providing
good standardization across all patients examined.
This study does have limitations. In the United
States, injection drug use is the primary risk factor
for HCV infection.2 As this population has multiple
other pregnancy co-morbidities and adverse fetal
outcomes it can be difficult to limit confounding
variables.23 Information regarding hepatitis B status,
history of cholecystectomy, sub-clinical cholestasis
or other processes that could affect serum bile acids
levels would further enhance our understanding.
Also, we did not differentiate the degree of elevation
of the hepatitis C viral load. Future studies could
examine the relationship between outcome
variables when the viral load is high, greater than
1 million versus low, less than 1 million. The study
was also limited by the number of patients. A large,
multi-center prospective trial would enhance our
understanding of the effects of hepatitis C virus on
the fetal heart.
Fetal heart function, measured by the left
ventricular Tei index, may be affected by hepatitis
C in pregnancy. The findings from this study
warrant further evaluation in a prospective study
with a control group. Liver disease in pregnancy
manifested by hepatitis C may not be benign in the
fetal myocardium.
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